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A B S T R A C T
The purpose of this study was to determine the prevalence of ocular surface disease symptoms and the state of the tear
film among patients with glaucoma who are receiving topical intraocular pressure lowering monotherapy. 62 responders
were divided in 2 groups: 32 glaucoma patients and 30 healthy individuals. Tear film break-up time (TBUT), Schirmer
1 testing and ocular surface disease questionnaire were performed in both groups. 50% glaucoma patients and 25% con-
trol group participants had dry eye symptoms. Advanced disorder in TBUT was found in seven 21.9% glaucoma patients
and was not found in the control group. Basal tear secretion measured by Schirmer 1 testing was found reduced in 87%
of glaucoma patients and in 16.7% control group patients. Glaucoma patients on topical intraocular pressure lowering
monotherapy showed a significantly higher prevalence of ocular surface disease symptoms, significantly reduced basal
tear secretion and destabilisation of tear film in comparison with healthy volunteers.
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Introduction
Glaucoma is a chronic condition and one of the lead-
ing causes of blindness in the world. Medical therapy
constitutes the usual first line treatment for glaucoma-
tous patients who often use topical therapy for many
years1. However, adverse effects associated with topical
medication may have a negative effect on patient adher-
ence to medical treatment, doctor-patient relationship,
and patient quality of life2. Topically administrated med-
ication affects the structure and the integrity of the ocu-
lar surface.1 Side effects of eye drops could be due to the
active component or preservatives2.
Ocular surface disease (OSD) and glaucoma are both
prevalent in the elderly and are common comorbidities in
the same patient. Topical intraocular pressure lowering
therapies for glaucoma have been found to aggravate
OSD by inducing symptoms such as dryness and irrita-
tion3. There is evidence that almost 11% of patients ages
of 40 to 59 is affected with ocular surface disease4.
The most commonly used preservative is benzako-
nium chloride2. This detergent effect in combination
with partial distribution of mucous gland cells is respon-
sible for the the induced instability of the lacrymal film,
involving a decrease of the tear break-up time. This re-
sults in symptoms like irritation. An immunologic reac-
tion with an increased presence of lymphocytes, macro-
phages, and Langerhans cells is reported following to the
chronic application of preservatives. This inflammation
can results in subconjunctival fibrosis2 It has been re-
congnized recently that long-term topical treatments for
open-angle glaucoma may constitute a significant risk
factor of failure of glaucoma filtering surgery5.
The purpose of this study was to determine the preva-
lence of ocular surface disease symptoms and the state of
the tear film among patients with glaucoma who are re-
ceiving topical intraocular pressure lowering therapy.
Subjects and Methods
This was a prospective study conducted at Department
of Ophthalmology, Zagreb University Hospital Center,
Zagreb, Croatia, and was approved by appropriate institu-
tional review boards. All 62 participating patients pro-
vided written informed consent. 32 glaucoma patients
with clinical diagnosis of primary open-angle glaucoma in
both eyes underwent the study. The control group con-
sisted of 30 healthy participants who were mostly accom-
panying persons, selected randomly from the waiting
room. All glaucoma and healthy participants underwent a
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complete ophthalmological examination. Excluded from
the study were participants with any abnormality having
dry eye treated with the use of punctual plugs, punctual
cautery, cyclosporine, topical ocular corticosteroids, using
artificial tears not discontinued prior to first study visit,
having keratorefractive ocular laser procedures, corneal
surgery, patients with progressive retinal or optic nerve
disease, with severe central visual field loss, patients with
any history of infectious or inflammatory ocular condi-
tions, patients having ocular trauma within 6months, any
systemic medications on a chronic basis that have not
been on a stable dosing regimen for 1 month prior to the
study, and history of intolerance or hypersensitivity to any
component of the test articles.
All recruited glaucoma participants were receiving
topical antiglaucoma medication treatment of 1 anti-
glaucoma drug (monotherapy) for 6 months or longer.
Demographic information, a medical history and medica-
tion usage were recorded. Measurement of basal tear se-
cretion was performed by Schirmer test 1:60 seconds af-
ter eye drop of topical anesthetic tetracain clorid 0.5%,
the tear film was sponged with a cotton swab, a standard
test strip was placed in the outer third of the lower eyelid
and removed after five minutes. The length of the moist-
ened strip was measured. Normal finding is 10 mm and
more, moderate disorder is 6–9 mm and advanced disor-
der is less than 6 mm.
Tear film break-up time (TBUT, fluorescein break up
time) is a method of determining the stability of the tear
film and checking for evaporative dry eye. Fluorescein
dye was instilled by wetting a dry fluorescein-impreg-
nated paper strip with a drop of saline and placing on the
bulbar cornea for a brief moment. After 1 or 2 blinks, the
tear film took on a uniform fluorescent green appear-
ance. Patient was asked not to blink within 60 seconds.
The time elapsed between a complete blink, and the ap-
pearance of the first dark spot or streak, was measured
and taken to be break up time. Five successive measures
were taken and the mean value was calculated. Normal
finding is 10 seconds and more, moderate disorder is 6–9
seconds, advanced disorder is less than 5 seconds.
All participants completed the ocular surface disease
questionnaire, with 5 questions designed to provide a
rapid assessment of OSD related to chronic dry eye, its
severity, and its impact on the patient’s ability to func-
tion. Affirmative answers to 4 of 5 questions were recog-
nized as finding of ocular surface disease symtoms.
Statistics
All data were grouped into categories. Descriptive sta-
tistics were generated from those scores, with mean ±SD
reported. Subjective data were analyzed by a c2-test. P
values of <0.05 were taken to be significant. Objective
data were analyzed.
Results
Sixty-two participants were recruited, thirty two pa-
tients with open angle glaucoma (glaucoma group) – fif-
teen men and seventeen women, mean age 62.7 years,
and thirty healthy respondents (control group). – four-
teen men and sixteen women, mean age 57.9 years.
There was no statistically significant difference between
two groups, regarding sex and age. Cardiac diseases,
blood pressure medication, rheumatic diseases, sleeping
and pain relief medications, were equaly distributed be-
tween both groups, with no statistically significant dif-
ference between groups (Table 1). Sixteen glaucoma pa-
tients (50%) and six in the control group (25%) had dry
eye symptoms, according to ocular surface disease ques-
tionnaire answers.
The number of eyes with abnormal values of tear
break-up time (TBUT) was higher in glaucoma group in
comparison with control group. The number of eyes with
normal finding of tear film break-up time of 10 seconds
was nine (28%) in glaucoma group towards twenty (66.7%)
in the control group. Moderate disorder in TBUT was
present in sixteen (50.1%) glaucoma patients and in ten
(33.4%) of the control group patients. Advanced disorder
in TBUT was found in seven (21.9%%) glaucoma pa-
tients and was not found in the control group (Table 2).
Basal tear secretion measured by Schirmer 1 testing
was found reduced in 87.0% of glaucoma patients: statis-
tically relevant higher number of glaucoma subjects had
advanced disorder in comparison with control group
(59.4% towards 16.7%). There was no statistically signifi-
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TABLE 1
DEMOGRAPHIC AND MEDICAL CHARACTERISTICS OF GLAUCOMA PATIENTS AND CONTROL GROUP
Glaucoma group Control group
Mean age (years) 62.7 57.9
Range age (years) 51–70 42–67
Men 17 15
Women 15 15
Cardiac disease/ Blood pressure medication 15 (48.0%) 17 (51.0%)
Sedation /Sleeping medication 24 (77.8%) 20 (75.0%)
Rheumatism and pain relief medications 24 (74.8%) 25 (85.0%)
Subjective symptoms of dry eye 16 (50.0%) 8 (26.7%)
Total 32 30
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cant difference in moderate disorder (28.1% towards
30.0% in the control group). Statistically significant hig-
her number of patients from the control group (53.3%)
had Schirmer testing value of 10 seconds and more in
comparison to glaucoma group (12.5%) (Table 3).
Discussion
The only proven and accepted method of preserving
visual function in glaucoma patients is to reduce intra-
ocular pressure level1. Chronic use of most intraocular
pressure lowering eye drops is often associated with vari-
ous adverse reactions: allergies, contact dermatitis, pun-
ctate keratitis and dry eye symptoms7. Changes in ocular
surface caused by antiglaucomaous eye drops were ob-
served as a decresae in BUT at 20 weeks after introduc-
tion of eye drop timolol8. Reduction of basal tears secre-
tion in glaucoma patients was reported in many stu-
dies9,10. Recent studies were investigating the effect of
topical glaucoma medication on tear film stability11,12
and corneal sensitivity13,14. 40% of glaucoma patients us-
ing 2or 3 topical intraocular pressure lowering medica-
tions exibit symptoms of ocular surface diesease15. An-
other study found a prevalence rate of nearly 60%.16 and
high correlation between clinical signs and symptoms,
including Schirmer testing, conjuctival and corneal stai-
ning with fluoresceine and lysamine green and evalua-
tion of tear break-up time. Destabilisation of tear film
and ocular surface symptoms have been observed with
essentially all intraocular pressure lowering therapies
and most likely are attributable to the nearly ubiquitous
preservative benzalkonium chloride16,17 There are many
evidences that ocular surface sindrom in glaucoma pa-
tients worsens with the number of intraocular pressure
medication used18.
Results of this study show a high prevalence of ocular
surface impairment in glaucomatous patients using only
one antiglaucoma medication. The frequency of both,
symptoms and objective signs of ocular surface irritation,
were higher in patients treated with antiglaucoma eye
drops compared to healthy individuals. Although the
prevalence of ocular surface syndrome has been reported
to be approximately 14–15% in the general population,19
we have demonstrated in the current study that the
prevalence of symptomatic ocular surface syndrome is
25% in the control group and nearly 50% in glaucoma
group. The reason for this finding lies probably in rela-
tively higher mean age of our control group (57.9 years)
as it is well known that older patients have reduced tear
film.4 Also is importaint to have in mind that side effects
are often very difficult to identify because they mostly oc-
cur in a delayed or poorly specific manner. Therefor mild
symptoms should not be underestimated, neglected, or
denied, because they may very well be the apparent man-
ifestations of more severe, potentially threatening sub-
clinical reactions that may later cause major concerns20.
The film stability, measured by TBUT, as Advanced dis-
order in TBUT was found in seven (21.9%) glaucoma pa-
tients and was not found in the control group. Basal tear
secretion measured by Schirmer 1 testing was found re-
duced in 87% of our glaucoma patients.
Conclusion
Results of this study demonstrate that patients with
glaucoma receiving topical intraocular pressure lowering
monotherapy have a significantly higher prevalence of
ocular surface disease symptoms, significantly reduced
basal tear secretion and destabilisation of tear film in
comparison with healthy volunteers.
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TABLE 2
TEAR FILM BREAK-UP TIME (TBUT) IN GLAUCOMA PATIENTS AND IN THE CONTROL GROUP
Tear film break-up time (TBUT) in seconds Glaucoma Group Control Group
Normal finding (10 and more) 9 (28.0%) 20 (66.7%)
Moderate disorder (7–9) 10 (31.3%) 5 (16.7%)
Moderate disorder (4–6) 6 (18.8%) 5 (16.7%)
Advanced disorder (less than 4) 7 (21.9%) 0 (0%)
There is a statistically relevant higher number of glaucoma subjects with TBUT of less 4 (advanced disorder). There is a statistically
relevant higher number of the control group subjects with TBUT of 10 or more (normal finding) X2 = 12.879, p<0.05.
TABLE 3
FINDING OF SCHIRMER 1 TESTING IN GLAUCOMA PATIENTS AND IN THE CONTROL GROUP
Shirmer 1 testing (mm) Glaucoma group Control group
Normal finding (10 and more) 4 (12.5%) 16 (53.3%)
Moderate disorder (6–9) 9 (28.1%) 9 (30.0%)
Advanced disorder (less than 6) 19 (59.4%) 5 (16.7%)
Statistically relevant higher number of glaucoma subjects had Schirmer value of less than 6. Statistically higher number of patients
from the control group had Schirmer value of 10 or more. x2= 15.318, p<0.05.
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STANJE SUZNOG FILMA GLAUKOMSKIH PACIJENATA
S A @ E T A K
Cilj studije je bilo odre|ivanje pojavnosti simptoma suhog oka i stanja suznog filma u glaukomskih bolesnika koji su
lije~eni antiglaukomskim lijekovima u obliku kapljica. Glaukomski pacijenti su primali samo jednu vrstu kapi. U istra-
`ivanju je sudjelovalo 62 ispitanika koji su bili podijeljeni u dvije skupine: 32 glaukomska ispitanika i 30 zdravih ispita-
nika kontrolne skupine. Vrijeme pucanja suznog filma (TBUT Tear film break-up time), Schirmer 1 test i standar-
dizirani upitnik o simptomima suhog oka provedeni su u obje skupine ispitanika. 50% glaukomskih ispitanika i 25%
ispitanika kontrolne skupine imali su simptome suhog oka. Uznapredovala disfunkcija suznog filma (skra}eno vrijeme
pucanja suznog filma – TBUT) ustanovljena je samo u skupini glaukomskih ispitanika (21,9%). Reduciranu bazalnu
sekreciju mjerenu Schirmer 1 testom imalo je 87% ispitanika glaukomske skupine i 16,7% ispitanika kontrolne skupi-
ne. Glaukomski pacijenti lije~eni monoterapijom u obliku kapi imali su zna~ajno vi{e simptoma povezanih sa suho}om
povr{ine oka, sni`enu bazalnu sekreciju suza kao i disfunkciju suznog filma u odnosu na kontrolnu skupinu zdravih
ispitanika.
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